ArticleThe Eurasian journal of medicine2026
A Dangerous Partnership: Malignancy and Antiphospholipid Antibodies.
Article in The Eurasian journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is characterized by persistent antiphospholipid antibodies (aPL) associated with thrombotic and/or obstetric complications. Malignancies are strongly prothrombotic, and growing evidence suggests clinically relevant interactions between aPL and cancer. Interpretation remains challenging because many oncologic studies rely on non-criteria aPL profiles, low titers, or single-time measurements that may not reflect clinically meaningful APS. The aim was to summarize current evidence regarding aPL in malignancy, focusing on prevalence, laboratory profiles, thrombotic manifestations, catastrophic antiphospholipid syndrome (CAPS), paraneoplastic associations, and potential clinical implications in oncology patients. A focused narrative review was conducted using PubMed/MEDLINE and PubMed Central (through October 26, 2025). Predefined search strategies emphasized antibody profile, persistence (≥12 weeks when available), tumor type, and thrombotic outcomes. Studies were selected for clinical relevance and verifiability, with structured synthesis of key findings. Meta-analytic data demonstrate increased anticardiolipin positivity in gastrointestinal, genitourinary, and lung cancers, whereas lupus anticoagulant and anti-β2GPI findings remain heterogeneous. Antiphospholipid antibodies positivity was frequently transient or low titer, limiting clinical interpretation. Persistent or high-risk aPL profiles were associated with increased thrombosis in selected subgroups. Catastrophic antiphospholipid syndrome and paraneoplastic APS have been reported in malignancy, and obstetric APS cohorts suggest a possible bidirectional relationship with cancer incidence. In conclusion, the malignancy-aPL interface involves increased antibody prevalence, phenotype-dependent thrombotic risk, CAPS association, and paraneoplastic mechanisms. Clinical interpretation must consider antibody profile and persistence, avoiding conclusions based on isolated positivity. Prospective studies are needed to clarify clinical relevance and guide screening strategies. Cite this article as: Carvalho JFd, Amadei LP, Rodrigues CEM. A dangerous partnership: malignancy and antiphospholipid antibodies. Eurasian J Med. 2026, 58(4), 1434, doi: 10.5152/ eurasianjmed.2026.261434.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.